Alpha cognition announces partial exercise of over-allotment option

Vancouver, british columbia & dallas--(business wire)--alpha cognition inc. (nasdaq: acog) (“alpha cognition”, or the “company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced that the underwriters of its underwritten u.s. public offering (the “offering”) have partially exercised their over-allotment option to purchase an additional 488,506 common shares at the public offering price of us$5.75 per share for an a.
ACOG Ratings Summary
ACOG Quant Ranking